首页> The American journal of cardiology> Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).

Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).

导出 LinkOut

翻译打印收藏纠错

第一作者： Serge,Korjian

第一单位： PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

作者： Serge,Korjian ^[1] ; Eugene,Braunwald ^[2] ; Yazan,Daaboul ^[1] ; Michael,Mi ^[1] ; Deepak L,Bhatt ^[2] ; Freek W A,Verheugt ^[3] ; Marc,Cohen ^[4] ; Christoph,Bode ^[5] ; Paul,Burton ^[6] ; Alexei N,Plotnikov ^[6] ; C Michael,Gibson ^[7]

作者单位： PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ^[1] TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ^[2] Radboud University, Nijmegen University Medical Center, Nijmegen, The Netherlands; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ^[3] Newark Beth Israel Medical Center, Rutgers University School of Medicine, Newark, New Jersey; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ^[4] University Hospital Freiburg, Freiburg, Germany; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ^[5] Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ^[6] PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: mgibson@bidmc.harvard.edu. ^[7]